Pacira BioSciences (PCRX) director receives new RSU and stock option awards

Rhea-AI Filing Summary

Pacira BioSciences director Michael J. Yang received new equity awards as part of his compensation. On June 10, 2026, he was granted 6,405 restricted stock units that will vest on June 10, 2027, if he remains in continuous service. Each unit converts into one share of common stock at vesting.

He also received a stock option for 10,891 shares of common stock at an exercise price of $23.42 per share. This option becomes exercisable on June 10, 2027, subject to the same service requirement, and expires on June 10, 2036. Following these awards, he directly holds 19,798 shares of common stock.

Insights

Equity compensation analyst

Routine director equity grants, adding RSUs and options with 2027 vesting.

Director Michael J. Yang received 6,405 restricted stock units and an option on 10,891 shares at an exercise price of $23.42 per share. Both awards vest or become exercisable on June 10, 2027, contingent on continued service.

These awards increase his direct holdings to 19,798 common shares and add a long-dated option expiring in 2036. The grants look like standard board compensation rather than market transactions, so they are generally interpreted as neutral, long-term incentive alignment rather than an active buy or sell signal.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider YANG MICHAEL J.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	10,891	$0.00	--
Grant/Award	Common Stock	6,405	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 10,891 shares (Direct, null); Common Stock — 19,798 shares (Direct, null)

Footnotes (1)

1. Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date.

Key Figures

RSU grant: 6,405 units Option grant size: 10,891 shares Option exercise price: $23.42 per share +3 more

6 metrics

RSU grant 6,405 units Restricted stock units granted June 10, 2026; vest June 10, 2027

Option grant size 10,891 shares Stock option covering common shares granted June 10, 2026

Option exercise price $23.42 per share Exercise price for 10,891-share stock option

Option expiration June 10, 2036 Expiration date of stock option if unexercised

Common shares after grant 19,798 shares Direct common stock holdings following RSU grant

Equity vesting date June 10, 2027 Vesting date for both RSUs and stock option

Key Terms

restricted stock units, stock option, continuous service, exercise price

4 terms

restricted stock units financial

"Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

stock option financial

"The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

continuous service financial

"provided that the reporting person remains in continuous service with the issuer through the vesting date"

exercise price financial

"Stock Option (Right to Buy) ... conversion_or_exercise_price: "23.4200""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

YANG MICHAEL J.

(Last) (First) (Middle)

C/O PACIRA BIOSCIENCES, INC.

2000 SIERRA POINT PARKWAY, SUITE 900

(Street)

BRISBANE CALIFORNIA 94005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pacira BioSciences, Inc. [ PCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/10/2026		A		6,405(1)	A	$0	19,798	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$23.42	06/10/2026		A		10,891		06/10/2027(2)	06/10/2036	Common Stock	10,891	$0	10,891	D

Explanation of Responses:

1. Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

2. The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date.

Remarks:

	/s/ Kristen Williams, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did Pacira BioSciences (PCRX) director Michael J. Yang receive?

Michael J. Yang received 6,405 restricted stock units and a stock option for 10,891 shares of Pacira BioSciences common stock. These awards were granted on June 10, 2026, as part of his director compensation package, subject to standard vesting conditions.

When do Michael J. Yang’s new Pacira BioSciences RSUs and options vest?

Both the 6,405 restricted stock units and the option for 10,891 shares vest or become exercisable on June 10, 2027. Vesting requires that Yang remain in continuous service with Pacira BioSciences through that vesting date, according to the Form 4 disclosure.

What is the exercise price of Michael J. Yang’s new Pacira BioSciences stock option?

The new stock option granted to Michael J. Yang has an exercise price of $23.42 per share. It covers 10,891 shares of Pacira BioSciences common stock, becomes exercisable on June 10, 2027, and carries an expiration date of June 10, 2036, if not exercised earlier.

How many Pacira BioSciences shares does Michael J. Yang hold after these grants?

After the June 10, 2026 grants, Michael J. Yang directly holds 19,798 shares of Pacira BioSciences common stock. This figure reflects his position following the RSU award, separate from the 10,891-share stock option that represents a future right to acquire additional shares.

Are Michael J. Yang’s Pacira BioSciences Form 4 transactions open-market buys or sales?

The transactions reported are equity grants, not open-market buys or sales. They consist of a restricted stock unit award and a stock option grant, both provided at no cash cost to Yang, as compensation contingent on continued service with Pacira BioSciences through June 10, 2027.